Morgan Keegan's EPS estimate on RadNet RDNT of ($0.03) is $0.03 above the First Call consensus and up from ($0.09) in the prior year period. Morgan Keegan believes a better measure of RadNet profitability is adjusted EBITDA. It has modeled $26.2 million versus $20.5 million in the prior year period. Since adjusted EBITDA is a non-GAAP measure there is no consensus estimate.
Morgan Keegan expects the company to continue to generate growth despite continued utilization prressures on imaging services arising from the weak economy and lack of patient visits to referring physicians.
Morgan Keegan believes RadNet, as a geographically concentrated operator of multimodality imaging centers, is positioned to consolidate the highly fragmented imaging sector. Medicare reimbursement cuts, combined with managed care utilization management and credentialing efforts, are squeezing small players and physician-owned centers, creating accretive acquisition opportunities in an industry with mid-single digit annual volume growth.
Morgan Keegan has a $4.30 PT and Outperform rating on RDNT
RDNT closed Tuesday at $3.85
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in